Plus Therapeutics Inc (PSTV) - Total Liabilities
Based on the latest financial reports, Plus Therapeutics Inc (PSTV) has total liabilities worth $12.33 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Plus Therapeutics Inc - Total Liabilities Trend (1998–2025)
This chart illustrates how Plus Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Plus Therapeutics Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Plus Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Plus Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Archtis Ltd
AU:AR9
|
Australia | AU$15.84 Million |
|
Etiler İnci Bufe Gida Sanayi ve Dis Ticaret AS
IS:ETILR
|
Turkey | TL802.86 Million |
|
DCM Nouvelle Limited
NSE:DCMNVL
|
India | Rs2.37 Billion |
|
Wayi International Digital Entertainment Co
TWO:3086
|
Taiwan | NT$31.83 Million |
|
Next Bt Co. Ltd
KQ:065170
|
Korea | ₩8.41 Billion |
|
Drax Group PLC
LSE:DRX
|
UK | GBX3.27 Billion |
|
Maquia Capital Acquisition Corp
NASDAQ:MAQC
|
USA | $9.56 Million |
|
Alam Maritim Resources Bhd
KLSE:5115
|
Malaysia | RM170.84 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down Plus Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Plus Therapeutics Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.23 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.76 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Plus Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Plus Therapeutics Inc (1998–2025)
The table below shows the annual total liabilities of Plus Therapeutics Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.33 Million | -20.88% |
| 2024-12-31 | $15.58 Million | +22.35% |
| 2023-12-31 | $12.74 Million | -26.90% |
| 2022-12-31 | $17.42 Million | +56.32% |
| 2021-12-31 | $11.14 Million | +22.82% |
| 2020-12-31 | $9.07 Million | -58.88% |
| 2019-12-31 | $22.07 Million | +17.60% |
| 2018-12-31 | $18.77 Million | +0.81% |
| 2017-12-31 | $18.61 Million | -21.20% |
| 2016-12-31 | $23.62 Million | -7.33% |
| 2015-12-31 | $25.49 Million | -42.61% |
| 2014-12-31 | $44.42 Million | +14.11% |
| 2013-12-31 | $38.93 Million | +5.80% |
| 2012-12-31 | $36.80 Million | -11.52% |
| 2011-12-31 | $41.59 Million | -4.34% |
| 2010-12-31 | $43.47 Million | +53.04% |
| 2009-12-31 | $28.41 Million | -14.76% |
| 2008-12-31 | $33.33 Million | +7.83% |
| 2007-12-31 | $30.91 Million | -13.38% |
| 2006-12-31 | $35.68 Million | +3.74% |
| 2005-12-31 | $34.40 Million | +172.18% |
| 2004-12-31 | $12.64 Million | -4.12% |
| 2003-12-31 | $13.18 Million | -1.08% |
| 2002-12-31 | $13.32 Million | +186.11% |
| 2001-12-31 | $4.66 Million | +58.73% |
| 2000-12-31 | $2.93 Million | -74.97% |
| 1999-12-31 | $11.72 Million | +1185.31% |
| 1998-12-31 | $912.00K | -- |
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric br… Read more